[8-K] INSPIRE VETERINARY PARTNERS, INC. Reports Material Event

Rhea-AI Filing Summary

Inspire Veterinary Partners, Inc. reported that Nasdaq has notified the company its common stock no longer meets the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) after 30 consecutive business days with a low closing bid price. Nasdaq stated the company’s securities would be suspended from trading on the Nasdaq Capital Market at the opening of business on November 24, 2025, and a Form 25-NSE would be filed to remove the securities from listing and registration, unless the company appealed. The company requested a hearing before Nasdaq’s Hearings Panel by November 20, 2025, which stays any suspension or delisting action during the process. On November 21, 2025, the company was informed that the hearing is scheduled for January 13, 2026, and it cautions there can be no assurance it will retain its Nasdaq listing or regain compliance.

Positive

• None.

Negative

• Nasdaq delisting risk disclosed: Nasdaq notified the company that its stock failed the minimum bid price requirement under Listing Rule 5550(a)(2) for 30 consecutive business days, and a delisting process has begun, subject to a hearing on January 13, 2026.

Insights

Equity markets and listing standards analyst

Nasdaq bid-price noncompliance puts Inspire Veterinary Partners’ listing at risk.

Inspire Veterinary Partners disclosed that its common stock has failed to meet Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) for 30 consecutive business days. Nasdaq indicated trading on the Nasdaq Capital Market would be suspended on November 24, 2025, with a Form 25-NSE to remove the securities from listing and registration.

The company requested a hearing with Nasdaq’s Hearings Panel by November 20, 2025, which stays any suspension or delisting while the process is pending. On November 21, 2025, it was advised that the hearing is scheduled for January 13, 2026. The company explicitly notes there is no assurance the Panel will grant continued listing or that it will regain compliance.

Loss of a Nasdaq listing can affect liquidity and accessibility for investors, as trading may move to less visible markets. The scheduled January 13, 2026 hearing is therefore a key procedural milestone, but outcomes will depend on the company’s ability to demonstrate a credible path back to compliance under Nasdaq’s rules.

false 0001939365 0001939365 2025-11-21 2025-11-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 21, 2025

INSPIRE VETERINARY PARTNERS, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-41792		85-4359258
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

780 Lynnhaven Parkway, Suite 400 Virginia Beach, VA		23452
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (757) 734-5464

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001		IVP		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As reported previously on the Current Report on Form 8-K filed by Inspire Veterinary Partners, Inc. (the “Company”) on November 17, 2025, the Company received a notice letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share, for the prior 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2).

The Notice stated that the Company’s securities would be suspended from trading on The Nasdaq Capital Market at the opening of business on November 24, 2025, and a Form 25-NSE would be filed with the U.S. Securities and Exchange Commission, which would remove the Company’s securities from listing and registration on Nasdaq, unless the Company requested an appeal of such determination to Nasdaq’s Hearings Panel (the “Panel”) by November 20, 2025. The Company requested a hearing before the prescribed date, which request will stay any further suspension or delisting action by Nasdaq pending the ultimate conclusion of the hearing process. On November 21, 2025, the Company was informed that the hearing is scheduled for January 13, 2026. There can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to regain compliance and thereafter maintain its listing on Nasdaq. 

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 24, 2025	INSPIRE VETERINARY PARTNERS, INC.
	By:	/s/ Kimball Carr
	Name:	Kimball Carr
	Title:	President and Chief Executive Officer

2

FAQ

Why did Inspire Veterinary Partners (IVP) receive a Nasdaq notice?

Inspire Veterinary Partners received a notice from Nasdaq because, based on the closing bid price of its common stock for the prior 30 consecutive business days, it was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

What potential action did Nasdaq indicate for IVP’s stock listing?

Nasdaq stated that Inspire Veterinary Partners’ securities would be suspended from trading on the Nasdaq Capital Market at the opening of business on November 24, 2025, and that a Form 25-NSE would be filed to remove the securities from listing and registration, absent a timely appeal.

How did Inspire Veterinary Partners respond to the Nasdaq delisting notice?

Inspire Veterinary Partners requested a hearing before Nasdaq’s Hearings Panel by November 20, 2025, which stays any further suspension or delisting action while the hearing process is ongoing.

When is the Nasdaq Hearings Panel meeting for Inspire Veterinary Partners scheduled?

On November 21, 2025, Inspire Veterinary Partners was informed that its hearing before the Nasdaq Hearings Panel is scheduled for January 13, 2026.

Is there any assurance that Inspire Veterinary Partners will remain listed on Nasdaq?

No. The company states there can be no assurance that the Nasdaq Hearings Panel will grant its request for continued listing or that it will be able to regain compliance and maintain its Nasdaq listing.

What listing rule is Inspire Veterinary Partners out of compliance with on Nasdaq?

The company is out of compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2), which is based on the closing bid price over 30 consecutive business days.